Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Theracryf Plc | LSE:TCF | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.025 | 4.76% | 0.55 | 323,662 | 08:33:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.50 | 0.60 | 0.55 | 0.525 | 0.525 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 396k | -3.14M | -0.0073 | -0.75 | 2.24M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:04:39 | O | 210,000 | 0.527 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 15/11/2024 | 10:58 | UK RNS | Theracryf PLC Holding(s) in Company |
| 14/11/2024 | 15:24 | UK RNS | Theracryf PLC Issue of Equity and Total Voting Rights |
| 14/11/2024 | 11:00 | UK RNS | Theracryf PLC Notice of Results |
| 11/11/2024 | 07:00 | UK RNS | Theracryf PLC Publication of peer reviewed data |
| 04/11/2024 | 15:43 | ALNC |  EXECUTIVE CHANGES: Sanderson hires in UK and US; Oberon gets Penny |
| 04/11/2024 | 11:00 | UK RNS | Theracryf PLC Passing of Dr Sue Foden, Chair |
| 29/8/2024 | 06:00 | UK RNS | Theracryf PLC Grant of Options and PDMR Dealings |
| 08/8/2024 | 09:23 | UK RNS | Theracryf PLC Holding(s) in Company |
| 18/7/2024 | 14:02 | UK RNS | Theracryf PLC Result of AGM |
| 17/7/2024 | 09:26 | UK RNS | Theracryf PLC Holding(s) in Company |
Theracryf (TCF) Share Charts1 Year Theracryf Chart |
|
1 Month Theracryf Chart |
Intraday Theracryf Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/11/2024 | 16:27 | ENJOY turning a WRECK into STAR RUNNER? | 36 |
| 05/11/2024 | 18:18 | Theracryf the new Evgen onwards and upwards | 204 |
| 29/9/2017 | 14:06 | Terra Catalyst Fund | 114 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:04:40 | 0.53 | 210,000 | 1,106.70 | O |
| 08:33:27 | 0.55 | 100,000 | 550.00 | O |
| 08:31:45 | 0.55 | 13,662 | 75.00 | O |
| 2024-11-20 16:12:14 | 0.52 | 40,000 | 207.00 | O |
| 2024-11-20 14:34:46 | 0.55 | 245,513 | 1,338.05 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Theracryf Daily Update Theracryf Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TCF. The last closing price for Theracryf was 0.53p.Theracryf currently has 427,346,895 shares in issue. The market capitalisation of Theracryf is £2,350,408. Theracryf has a price to earnings ratio (PE ratio) of -0.75. This morning TCF shares opened at 0.53p |
Posted at 14/11/2024 15:37 by tomboyb I know 0.25p is ord -They have not exactly specified the price at which the shares were given have they - That was only my assumption as options were also given at ord - |
Posted at 14/11/2024 15:36 by markth126 Wake up, they are 0.25p shares that's not price they have been issued at |
Posted at 14/11/2024 15:36 by tomboyb TCF had £2million pounds left at the end of March -They will need to raise very soon - |
Posted at 06/11/2024 09:01 by clocktower Well the Trump supporters and the markets seem euphorice this morning, and you never know TCF might soon benefit from the excitment in the market, and small pharma stocks may well become attractive once again.Only takes a bit of good news or a new deal and these sort of stocks fly, and become attractive because of the tax advantages in the UK. |
Posted at 05/11/2024 18:18 by lovewinshatelosses Yep. Final tranche today. It was an aggregate meaty loss, but AIM education costs money, so cheap in that sense :)Did not try to dump the lot in one go, because I probably would not have even got the lowest price, which was the print today. Touch wood, I have done fairly well in the past few years, so the dent in the p/f has long since been smoothed over. Luckily I did not keep pouring more good money after bad in this one, since my last purchase here (cannot remember exactly when it was). Bitterness will not get your money back, so always best to try and take it on the chin and learn from it, IMO. Even with the dodgy names, which the authorities seem reluctant to deal with (again IMO). Not saying this is one of those, but I think you could make a compelling case for investors having, at the very least, being badly misled here over a few years now. Ground which has already been covered extensively over quite some time, so no need for me to repeat it. Good luck to you too and I hope your investments and trades elsewhere prosper. |
Posted at 01/11/2024 11:58 by clocktower I am not familiar with the UK tax regime but reading about the capital gains tax changes, would I be correct that some ISA investors might have been selling up across the board to ensure they were not going to be hit by the recent budget?Selling their whole portfolio even if it included duffers like this, which would be responsible in part for the very low share price. I would appreciate it is someone could enlighten me on the subject. |
Posted at 31/10/2024 14:27 by xxproinvestorxx Once Stalicla complete their series C raise, where they are targeting $60-75m, I have no doubt that we'll receive news on them paying us the money owed and their plans to advance STP2 into Phase 2. After all, STP2 has been validated by them as the primary candidate to treat Phenotype 2 ASD, which has a total addressable market in excess of $2B. Clock - Stalicla don't currently have the funds to buy out Theracryf (maybe after series C raise?), and I highly doubt 1p would be accepted by most shareholders, nor would I expect the bod to put forward such a lowball offer to shareholders.The share price is where it is due to several factors and I completely disagree regarding your comments on the share price being where it is due to Stalicla having no intention of ever paying the money for P1 trial completion. The uncertainty is why we are where we are, combined with the wider aim and small biotech environment. |
Posted at 12/6/2024 13:46 by clocktower Great volume once again, it seems to be building up a head of steam before tomorrows R & D update, which based on the buying of late is likely to send the share price a lot higher, as it is nodoubt very positive, as it is unlikely we would have seen the slow increase in the share price lately, if it were not. |
Posted at 04/6/2024 19:03 by terrydevlin1 Good luck Mark and CT. Whilst the Stalicla deal is still live I can’t see how this can go down much lower. But that deal looks to be on the rocks IMO. The fact TCF no longer mentioned up to $5.5m expected this year in the full results and Stalicla also removed from their website that this would go into phase 2 in 2024, it doesn’t look good. If the deal collapses this share price will be 0.1p and it’s game over. I question where is the money going to come from to bankroll this company? TCF needs between £3m and £4m a year which is enormous sums of money.I’ve been doing alright recently on the virtual dogs at the bookies, I’d rather stick a grand on a virtual dog than this dog of a share. |
Posted at 26/5/2024 11:34 by terrydevlin1 I don’t know how anyone can think the results will be positive at all. Terrible 12 months here. No income, Juvenesense deal collapsed, Stalicla dispute, no new contracts signed, a share placing, money running out, next to no news on SFX-01 progressing. I think TCF may have a decent drug in SFX-01 buy they can’t afford to do any trials and can’t get anyone to trial it for them. Even if TCF get the $5.5m they hoped by the end of the year, where is the next income coming from? Stalicla payments clearly can’t be relied on. The end goal is already written here, another share placement which happens every 2 years is inevitable at some point. The shares will be diluted so much that there is no possibility of shareholders making any money here. There is no hope of TCF ever succeeding now. Don’t waste your time or money here. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
